Replimune Group, Inc.
REPL
Positions held
Your positionsREPL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Replimune Group is positioned in the rapidly growing biotechnology sector, focusing on innovative therapies that could address significant unmet medical needs.
- The company's market cap stands at approximately $1.25 billion, indicating strong investor interest and potential for growth.
- Analysts recommend a 'buy' with a target mean price of $19.5, suggesting a significant upside from current levels.
- Replimune has not generated any revenue in recent quarters, which raises concerns about its financial sustainability.
- The company reported a net income loss of $313.94 million for the year 2026, reflecting ongoing financial challenges.
- With a debt-to-equity ratio of 105.99, the company is heavily leveraged, which could pose risks in a volatile market.
Fundamentals
| Market cap | $1.23B | Enterprise value | $1.15B | Trailing P/E | — | Forward P/E | -7.17 |
| PEG | — | Price / book | 10.37 | Beta | 0.94 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -134.3% | ROA | -51.3% | Debt / equity | 1.06 |
| Current ratio | 5.23 | Free cash flow | -$171.67M | Analyst recommendation | buy | Mean target | $19.50 |
| 52w high | $16.33 | 52w low | $1.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$69.8M | -$73.2M | -$70.9M | -$83.1M | -$86.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$68.0M | -$72.9M | -$71.5M | -$83.9M | -$90.0M | — |
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$314M | -$247M | -$216M | -$174M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$318M | -$260M | -$233M | -$174M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
2026-10-01 · Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
2026-09-16 · Trump Administration Shift Puts This Corner of Biotech Back in Favor
2026-09-03 · Replimune to Present at the Cantor Global Healthcare Conference 2026
2026-08-27 · Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
2026-08-19 · Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-14 · Replimune Fiscal Q1 Net Loss Narrows
2026-08-14 · Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
2026-08-13 · Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment
2026-08-11 · Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
2026-08-10 · REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
2026-08-10 · This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.
Price (daily)
Full chart · RSI · MACD · patterns